1
|
Blyakhman F, Fadeyev F, Safronov A, Terziyan T, Burban E, Shklyar T, Kurlyandskaya G. Iron Oxide Magnetic Nanoparticles Synthesized by Laser Target Evaporation Method for the Needs of Cancer Immunotherapy. MATERIALS (BASEL, SWITZERLAND) 2025; 18:2142. [PMID: 40363644 DOI: 10.3390/ma18092142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2025] [Revised: 04/25/2025] [Accepted: 05/04/2025] [Indexed: 05/15/2025]
Abstract
Administration of monocyte-derived dendritic cells (moDCs) sensitized by cancer-associated antigens to the patient is applied to boost the T-cell mediated anti-tumor immune response. Loading moDCs with magnetic nanoparticles (MNPs) and controlling their migration to lymph nodes by an external magnetic field is a way to improve the effectiveness of immunotherapy. In this study, spherical MNPs of maghemite iron oxide with a diameter of about 14 nm were synthesized by laser target evaporation method (LTE) and examined in the context of their prospective use for the needs of moDCs immunotherapy. Characterization of the physicochemical properties of MNPs and their stabilization in physiological media, as well as the magnetic properties of MNPs in the suspensions were considered in detail. The cytotoxic effect of MNPs in growth medium on the human moDCs and MNPs uptake by the cells were also estimated. We show that up-taken MNPs and MNPs in growth medium demonstrated cytotoxic effect only at high concentrations. At the same time, at low concentrations MNPs up-taken by moDCs increased their viability causing the stimulation effect. The evaluation of the quantity of MNPs, up-taken by cells, is possible by magnetometry even for the smallest γ-Fe2O3 concentrations.
Collapse
Affiliation(s)
- Felix Blyakhman
- Department of Biomedical Physics, Ural State Medical University, Ekaterinburg 620028, Russia
- Institute of Natural Sciences and Mathematics, Ural Federal University, Ekaterinburg 620002, Russia
| | - Fedor Fadeyev
- Department of Biomedical Physics, Ural State Medical University, Ekaterinburg 620028, Russia
- Institute of Medical Cell Technologies, Ekaterinburg 620026, Russia
| | - Alexander Safronov
- Institute of Natural Sciences and Mathematics, Ural Federal University, Ekaterinburg 620002, Russia
- Institute of Electrophysics UB RAS, Ekaterinburg 620016, Russia
| | - Tatiana Terziyan
- Institute of Natural Sciences and Mathematics, Ural Federal University, Ekaterinburg 620002, Russia
| | - Ekaterina Burban
- Institute of Natural Sciences and Mathematics, Ural Federal University, Ekaterinburg 620002, Russia
| | - Tatyana Shklyar
- Department of Biomedical Physics, Ural State Medical University, Ekaterinburg 620028, Russia
- Institute of Natural Sciences and Mathematics, Ural Federal University, Ekaterinburg 620002, Russia
| | - Galina Kurlyandskaya
- Institute of Natural Sciences and Mathematics, Ural Federal University, Ekaterinburg 620002, Russia
| |
Collapse
|
2
|
Rahman MA, Bissa M, Scinto H, Howe SE, Sarkis S, Ma ZM, Gutowska A, Jiang X, Luo CC, Schifanella L, Moles R, Silva de Castro I, Basu S, N'guessan KF, Williams LD, Becerra-Flores M, Doster MN, Hoang T, Choo-Wosoba H, Woode E, Sui Y, Tomaras GD, Paquin-Proulx D, Rao M, Talton JD, Kong XP, Zolla-Pazner S, Cardozo T, Franchini G, Berzofsky JA. Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response. Nat Commun 2024; 15:9102. [PMID: 39438480 PMCID: PMC11496677 DOI: 10.1038/s41467-024-53359-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2024] [Accepted: 10/09/2024] [Indexed: 10/25/2024] Open
Abstract
Systemic vaccination of macaques with V1-deleted (ΔV1) envelope immunogens reduce the risk of SIVmac251 acquisition by approximately 60%, with protective roles played by V2-specific ADCC and envelope-specific mucosal IL-17+NKp44+ innate lymphoid cells (ILCs). We investigated whether increased mucosal responses to V2 benefit vaccine efficacy by delivering oral nanoparticles (NPs) that release V2-scaffolded on Typhoid Toxin B (TTB) to the large intestine. Strikingly, mucosal immunization of male macaques abrogated vaccine efficacy with control TTB or empty NPs, but vaccine efficacy of up to 47.6% was preserved with V2-TTB NPs. The deleterious effects of NPs were linked to preferential recruitment of mucosal plasmacytoid dendritic cells (pDCs), reduction of protective mucosal NKp44+ ILCs, increased non-protective mucosal PMA/Ionomycin-induced IFN-γ+NKG2A-NKp44-ILCs, and increased levels of mucosal activated Ki67+CD4+ T cells, a potential target for virus infection. V2-TTB NP mucosal boosting rescued vaccine efficacy, likely via high avidity V2-specific antibodies mediating ADCC, and higher frequencies of mucosal NKp44+ ILCs and of ∆V1gp120 binding antibody-secreting B cells in the rectal mucosa. These findings emphasize the central role of systemic immunization and mucosal V2-specific antibodies in the protection afforded by ΔV1 envelope immunogens and encourage careful evaluation of vaccine delivery platforms to avoid inducing immune responses favorable to HIV transmission.
Collapse
Affiliation(s)
- Mohammad Arif Rahman
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Massimiliano Bissa
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Hanna Scinto
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Savannah E Howe
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Sarkis Sarkis
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Zhong-Min Ma
- California National Primate Research Center, University of California, Davis, Davis, USA
| | - Anna Gutowska
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Xunqing Jiang
- Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA
| | - Christina C Luo
- Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA
| | - Luca Schifanella
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Ramona Moles
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Isabela Silva de Castro
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Shraddha Basu
- United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
| | - Kombo F N'guessan
- United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
| | - LaTonya D Williams
- Center for Human Systems Immunology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA
| | | | - Melvin N Doster
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Tanya Hoang
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Hyoyoung Choo-Wosoba
- Office of Collaborative Biostatistics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Emmanuel Woode
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Yongjun Sui
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Georgia D Tomaras
- Center for Human Systems Immunology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA
| | - Dominic Paquin-Proulx
- United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA
| | - Mangala Rao
- United States Military HIV Research Program, CIDR, Walter Reed Army Institute of Research, Silver Spring, MD, USA
| | | | - Xiang-Peng Kong
- Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA
| | - Susan Zolla-Pazner
- Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, NY, New York, USA
| | - Timothy Cardozo
- New York University School of Medicine, NYU Langone Health, New York, NY, USA
| | - Genoveffa Franchini
- Animal Models and Retroviral Vaccines Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
| | - Jay A Berzofsky
- Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
| |
Collapse
|
3
|
Xu X, Yuan J, Zhu M, Gao J, Meng X, Wu Y, Li X, Tong P, Chen H. The potential of orally exposed risk factors and constituents aggravating food allergy: Possible mechanism and target cells. Compr Rev Food Sci Food Saf 2024; 23:e70014. [PMID: 39230383 DOI: 10.1111/1541-4337.70014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Revised: 08/10/2024] [Accepted: 08/18/2024] [Indexed: 09/05/2024]
Abstract
Food allergy is a significant concern for the health of humans worldwide. In addition to dietary exposure of food allergens, genetic and environmental factors also play an important role in the development of food allergy. However, only the tip of the iceberg of risk factors in food allergy has been identified. The importance of food allergy caused by orally exposed risk factors and constituents, including veterinary drugs, pesticides, processed foods/derivatives, nanoparticles, microplastics, pathogens, toxins, food additives, dietary intake of salt/sugar/total fat, vitamin D, and therapeutic drugs, are highlighted and discussed in this review. Moreover, the epithelial barrier hypothesis, which is closely associated with the occurrence of food allergy, is also introduced. Additionally, several orally exposed risk factors and constituents that have been reported to disrupt the epithelial barrier are elucidated. Finally, the possible mechanisms and key immune cells of orally exposed risk factors and constituents in aggravating food allergy are overviewed. Further work should be conducted to define the specific mechanism by which these risk factors and constituents are driving food allergy, which will be of central importance to the targeted therapy of food allergy.
Collapse
Affiliation(s)
- Xiaoqian Xu
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- College of Food Science & Technology, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Jin Yuan
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- College of Food Science & Technology, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Mengting Zhu
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- College of Food Science & Technology, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Jinyan Gao
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- College of Food Science & Technology, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Xuanyi Meng
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- Sino-German Joint Research Institute, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Yong Wu
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- Sino-German Joint Research Institute, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Xin Li
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- College of Food Science & Technology, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Ping Tong
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| | - Hongbing Chen
- State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, P. R. China
- Sino-German Joint Research Institute, Nanchang University, Nanchang, P. R. China
- Jiangxi Province Key Laboratory of Food Allergy, Nanchang, P. R. China
| |
Collapse
|
4
|
Olšovská E, Mikušová ML, Tulinská J, Rollerová E, Vilamová Z, Líšková A, Horváthová M, Szabová M, Svoboda L, Gabor R, Hajnyš J, Dvorský R, Kukutschová J, Lukán N. Immunotoxicity of stainless-steel nanoparticles obtained after 3D printing. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY 2024; 272:116088. [PMID: 38350218 DOI: 10.1016/j.ecoenv.2024.116088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 01/30/2024] [Accepted: 02/06/2024] [Indexed: 02/15/2024]
Abstract
This study aims to investigate the in vitro effects of nanoparticles (NPs) produced during the selective laser melting (SLM) of 316 L stainless steel metal powder on the immune response in a human blood model. Experimental data did not reveal effect on viability of 316 L NPs for the tested doses. Functional immune assays showed a significant immunosuppressive effect of NPs. There was moderate stimulation (117%) of monocyte phagocytic activity without significant changes in phagocytic activity and respiratory burst of granulocytes. A significant dose-dependent increase in the levels of the pro-inflammatory cytokine TNF-a was found in blood cultures treated with NPs. On the contrary, IL-8 chemokine levels were significantly suppressed. The levels of the pro-inflammatory cytokine IL-6 were reduced by only a single concentration of NPs. These new findings can minimise potential health risks and indicate the need for more research in this area.
Collapse
Affiliation(s)
- Eva Olšovská
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic; Faculty of Material Science and Technology, Centre for Advanced Innovation Technologies, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic.
| | - Miroslava Lehotská Mikušová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Jana Tulinská
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Eva Rollerová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Zuzana Vilamová
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic; Faculty of Materials and Technology, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Aurélia Líšková
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Mira Horváthová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Michaela Szabová
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| | - Ladislav Svoboda
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Roman Gabor
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Jiří Hajnyš
- Department of Machining, Assembly and Engineering Metrology, Faculty of Mechanical Engineering, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Richard Dvorský
- Nanotechnology Centre, CEET, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Jana Kukutschová
- Faculty of Material Science and Technology, Centre for Advanced Innovation Technologies, VSB-Technical University of Ostrava, 17. listopadu 2172/15, Ostrava-Poruba 708 00, Czech Republic
| | - Norbert Lukán
- Institute of Immunology and Allergology, Faculty of Medicine, Slovak Medical University, Limbová 12, 833 03, Slovakia
| |
Collapse
|
5
|
de Macêdo LS, de Pinho SS, Silva AJD, de Moura IA, Espinoza BCF, da Conceição Viana Invenção M, Novis PVS, da Gama MATM, do Nascimento Carvalho M, Leal LRS, Cruz BIS, Bandeira BMA, Santos VEP, de Freitas AC. Understanding yeast shells: structure, properties and applications. ADMET AND DMPK 2024; 12:299-317. [PMID: 38720922 PMCID: PMC11075163 DOI: 10.5599/admet.2118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 02/13/2024] [Indexed: 05/12/2024] Open
Abstract
Background and purpose The employment of yeasts for biomedical purposes has become increasingly frequent for the delivery of prophylactic and therapeutic products. Its structural components, such as β-glucans, mannan, and chitin, can be explored as immunostimulators that show safety and low toxicity. Besides, this system minimizes antigen degradation after administration, facilitating the delivery to the target cells. Review approach This review sought to present molecules derived from yeast, called yeast shells (YS), and their applications as carrier vehicles for drugs, proteins, and nucleic acids for immunotherapy purposes. Furthermore, due to the diversity of information regarding the production and immunostimulation of these compounds, a survey of the protocols and immune response profiles generated was presented. Key results The use of YS has allowed the development of strategies that combine efficiency and effectiveness in antigen delivery. The capsular structure can be recognized and phagocytized by dendritic cells and macrophages. In addition, the combination with different molecules, such as nanoparticles or even additional adjuvants, improves the cargo loading, enhancing the system. Activation by specific immune pathways can also be achieved by different administration routes. Conclusion Yeast derivatives combined in different ways can increase immunostimulation, enhancing the delivery of medicines and vaccine antigens. These aspects, combined with the simplicity of the production steps, make these strategies more accessible to be applied in the prevention and treatment of various diseases.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Antonio Carlos de Freitas
- Laboratory of Molecular Studies and Experimental Therapy - LEMTE; Department of Genetics, Biosciences Center, Federal University of Pernambuco; Pernambuco - Recife 50670-901, Brazil
| |
Collapse
|
6
|
Wen H, Huo G, Qin C, Wu H, Wang D, Dan M, Geng X, Liu S. Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats. Sci Rep 2023; 13:21501. [PMID: 38057444 PMCID: PMC10700491 DOI: 10.1038/s41598-023-48742-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 11/29/2023] [Indexed: 12/08/2023] Open
Abstract
Polyethylene glycol-coated magnetic nanoparticles (PEGylated MNPs) have demonstrated prominent advantages in cancer diagnosis and hyperthermia therapy. However, there is currently lack of standard mode and sufficient toxicity data for determining the delayed risk of PEGylated MNPs. Nevertheless, the toxicity potentials, especially those associated with the oxidative stress, were ubiquitously reported. In this study, PEGylated MNPs and p-PEGylated MNPs were administrated to SD (Sprague Dawley) rats by single intravenously injection, and various toxicity indicators were monitored till 56 days post-administration for a comprehensive toxicity evaluation. We revealed that both nanoparticles could be rapidly cleared from plasma and enter tissues, such as, liver, kidneys and spleen, and p-PEGylated MNP is less prone to be accumulated in the tissues, indicating a lower toxicity risk. PEGylated MNPs were more likely to up-regulate the expression levels of Th2 type cytokines and trigger inflammatory pathways, but no related pathological change was found. Both MNPs are not mutagenic, while recoverable mild DNA damage associated with the presence of nanoparticles might also be observed. This study demonstrated a research approach for the non-clinical safety evaluation of nanoparticles. It also provided comprehensive valuable safety data for PEGylated and p-PEGylated MNPs, for promoting the clinical application and bio-medical translation of such MNPs with PEG modifications in the cancer diagnosis and therapy.
Collapse
Affiliation(s)
- Hairuo Wen
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
| | - Guitao Huo
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
| | - Chao Qin
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
| | - Hui Wu
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
- China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, People's Republic of China
| | - Dan Wang
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China
- China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, People's Republic of China
| | - Mo Dan
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
- State Key Laboratory of Novel Pharmaceutical Preparations and Excipients, CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, 050035, Hebei, People's Republic of China.
| | - Xingchao Geng
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
| | - Shujie Liu
- National Center for Safety Evaluation of Drugs, Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Institutes for Food and Drug Control, Beijing, 100176, People's Republic of China.
- Center for Drug Evaluation, National Medical Products Administration, Beijing, 100022, People's Republic of China.
| |
Collapse
|